Cidel Asset Management Inc. Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Cidel Asset Management Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 13.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,980 shares of the biopharmaceutical company’s stock after acquiring an additional 9,029 shares during the period. Cidel Asset Management Inc.’s holdings in Pfizer were worth $1,989,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brookstone Capital Management increased its position in Pfizer by 1.5% during the 3rd quarter. Brookstone Capital Management now owns 123,930 shares of the biopharmaceutical company’s stock valued at $3,587,000 after buying an additional 1,876 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors increased its holdings in shares of Pfizer by 25.4% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 12,223 shares of the biopharmaceutical company’s stock valued at $354,000 after acquiring an additional 2,479 shares in the last quarter. Wedmont Private Capital raised its position in shares of Pfizer by 5.6% in the 3rd quarter. Wedmont Private Capital now owns 37,473 shares of the biopharmaceutical company’s stock valued at $1,094,000 after purchasing an additional 1,994 shares during the last quarter. Quotient Wealth Partners LLC boosted its stake in Pfizer by 26.8% in the 3rd quarter. Quotient Wealth Partners LLC now owns 10,267 shares of the biopharmaceutical company’s stock worth $297,000 after purchasing an additional 2,172 shares in the last quarter. Finally, PPS&V Asset Management Consultants Inc. grew its position in Pfizer by 7.2% during the 3rd quarter. PPS&V Asset Management Consultants Inc. now owns 14,394 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 963 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.76 on Friday. The company has a market capitalization of $145.96 billion, a PE ratio of 18.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company’s fifty day moving average price is $26.29 and its 200 day moving average price is $27.77. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The company’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.68%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.